Earnings ·
EyePoint, Inc. reported second quarter 2026 financial results showing total net revenue of $0.5 million and a net loss…
EYPTEyePoint, Inc.
EyePoint, Inc. reported second quarter 2026 financial results showing total net revenue of $0.5 million and a net loss of $94.5 million, or ($1.09) per share, compared to $5.3 million in revenue and a $59.4 million net loss in the prior year period. Operating expenses increased to $97.9 million from $67.6 million due to ongoing Phase 3 clinical trials for DURAVYU and manufacturing scale-up. The company holds $180 million in cash and investments, providing operational runway into the fourth quarter of 2027. Clinically, top-line data for the pivotal Phase 3 LUGANO wet AMD trial is expected in August 2026, with LUCIA following in Q4 2026; DME trials COMO and CAPRI are fully enrolled with topline data anticipated in Q4 2027. EyePoint, Inc. operates as a clinical-stage biopharmaceutical company developing innovative therapeutics for serious retinal diseases.